C
Christopher L. Nobles
Researcher at University of Pennsylvania
Publications - 36
Citations - 3124
Christopher L. Nobles is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Antigen & T cell. The author has an hindex of 16, co-authored 32 publications receiving 1676 citations. Previous affiliations of Christopher L. Nobles include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer,Joseph A. Fraietta,Megan M. Davis,Adam D. Cohen,Kristy L. Weber,Eric Lancaster,Patricia A. Mangan,Irina Kulikovskaya,Minnal Gupta,Fang Chen,Lifeng Tian,Vanessa E. Gonzalez,Jun Xu,In-Young Jung,J. Joseph Melenhorst,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Avery L. Gaymon,Stephanie Desjardins,Anne Lamontagne,January Salas-Mckee,Andrew D. Fesnak,Don L. Siegel,Bruce L. Levine,Julie K. Jadlowsky,Regina M. Young,Anne Chew,Wei-Ting Hwang,Elizabeth O. Hexner,Beatriz M. Carreno,Christopher L. Nobles,Frederic D. Bushman,Kevin R. Parker,Yanyan Qi,Ansuman T. Satpathy,Howard Y. Chang,Yangbing Zhao,Simon F. Lacey,Carl H. June +40 more
TL;DR: This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
Journal ArticleDOI
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta,Christopher L. Nobles,Morgan A. Sammons,Morgan A. Sammons,Stefan Lundh,Shannon A. Carty,Shannon A. Carty,Tyler J. Reich,Alexandria P. Cogdill,Jennifer J.D. Morrissette,Jamie E. DeNizio,Shantan Reddy,Young Hwang,Mercy Gohil,Irina Kulikovskaya,Farzana Nazimuddin,Minnal Gupta,Fang Chen,John K. Everett,Katherine A. Alexander,Enrique Lin-Shiao,Marvin H. Gee,Xiaojun Liu,Regina M. Young,David E Ambrose,Yan Wang,Jun Xu,Martha S. Jordan,Katherine T. Marcucci,Bruce L. Levine,K. Christopher Garcia,Yangbing Zhao,Michael Kalos,David L. Porter,Rahul M. Kohli,Simon F. Lacey,Shelley L. Berger,Frederic D. Bushman,Carl H. June,J. Joseph Melenhorst +39 more
TL;DR: Genetically engineered T cells that induced remission in a patient with chronic lymphocytic leukaemia were found to have disruption of the TET2 gene, which caused T cell changes that potentiated their anti-tumour effects.
Journal ArticleDOI
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella,Jun Xu,David M. Barrett,Joseph A. Fraietta,Tyler J. Reich,David E Ambrose,Michael Klichinsky,Olga Shestova,Prachi R. Patel,Irina Kulikovskaya,Farzana Nazimuddin,Vijay Bhoj,Elena Orlando,Terry J. Fry,Hans Bitter,Shannon L. Maude,Bruce L. Levine,Christopher L. Nobles,Frederic D. Bushman,Regina M. Young,John Scholler,Saar Gill,Carl H. June,Stephan A. Grupp,Simon F. Lacey,J. Joseph Melenhorst +25 more
TL;DR: A patient relapsing 9 months after CD19-targeted CAR T cell infusion with CD19– leukemia that aberrantly expressed the anti-CD19 CAR was reported.
Journal ArticleDOI
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses
Katherine M. Bruner,Katherine M. Bruner,Zheng Wang,Francesco R. Simonetti,Alexandra M. Bender,Kyungyoon J. Kwon,Srona Sengupta,Emily J. Fray,Subul A. Beg,Annukka A.R. Antar,Katharine M. Jenike,Lynn N. Bertagnolli,Adam A. Capoferri,Joshua T. Kufera,Andrew E. Timmons,Christopher L. Nobles,John R. Gregg,Nikolas Wada,Ya Chi Ho,Ya Chi Ho,Hao Zhang,Joseph B. Margolick,Joel N. Blankson,Steven G. Deeks,Frederic D. Bushman,Janet D. Siliciano,Gregory M. Laird,Robert F. Siliciano,Robert F. Siliciano +28 more
TL;DR: It is shown that the dynamics of cells that carry intact and defective proviruses are different in vitro and in vivo, and these findings have implications for targeting the intact provirus that are a barrier to curing HIV infection.
Journal ArticleDOI
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
J. Joseph Melenhorst,Gregory M. Chen,Meng Wang,David L. Porter,Changya Chen,McKensie Collins,Peng Gao,Shovik Bandyopadhyay,Hongxing Sun,Ziran Zhao,Stefan Lundh,Iulian Pruteanu-Malinici,Christopher L. Nobles,Sayantan Maji,Noelle V. Frey,Saar Gill,Lifeng Tian,Irina Kulikovskaya,Minnal Gupta,David E Ambrose,Megan M. Davis,Joseph A. Fraietta,Jennifer Brogdon,Regina M. Young,Anne Chew,Bruce L. Levine,Don L. Siegel,Cécile Alanio,E. John Wherry,Frederic D. Bushman,Simon F. Lacey,Kai Tan,Carl H. June +32 more
TL;DR: In this article , the authors studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia who achieved a complete remission in 2010.